MicroRNA biomarkers in whole blood for detection of pancreatic cancer
…, D Calatayud, SE Nielsen, M Yilmaz, NH Holländer… - Jama, 2014 - jamanetwork.com
Importance Biomarkers for the early diagnosis of patients with pancreatic cancer are needed
to improve prognosis. Objectives To describe differences in microRNA expression in whole …
to improve prognosis. Objectives To describe differences in microRNA expression in whole …
[HTML][HTML] 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non …
…, MP Saunders, J Cassidy, NH Hollander… - The Lancet …, 2018 - thelancet.com
Background 6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant
treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-…
treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-…
Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high …
…, T Yamanaka, I Boukovinas, NH Hollander… - 2019 - ascopubs.org
3501 Background: 6m of oxaliplatin-based treatment is an option as adj chemotherapy for
patients with high risk stage II CC (T4, inadequate nodal harvest, poorly differentiated, …
patients with high risk stage II CC (T4, inadequate nodal harvest, poorly differentiated, …
[HTML][HTML] Radiotherapy for metastatic spinal cord compression with increased radiation doses (RAMSES-01): A prospective multicenter study
…, N Jankarashvili, S Janssen, D Olbrich, NH Holländer - BMC cancer, 2019 - Springer
Background Patients with metastatic spinal cord compression (MSCC) and favorable survival
prognoses can benefit from radiation doses greater than 30Gy in 10 fractions in terms of …
prognoses can benefit from radiation doses greater than 30Gy in 10 fractions in terms of …
Evaluation of the HemoCue WBC DIFF in leukopenic patient samples
DK Kur, N Agersnap, NH Holländer… - International Journal …, 2020 - Wiley Online Library
Background White blood cell (WBC) counts are used to monitor bone marrow function and to
screen for infections. The HemoCue WBC DIFF Point‐Of‐Care (POC) instrument classifies …
screen for infections. The HemoCue WBC DIFF Point‐Of‐Care (POC) instrument classifies …
[HTML][HTML] 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
…, AH Briggs, J Cassidy, NH Hollander… - Health Technology …, 2019 - ncbi.nlm.nih.gov
BACKGROUND Oxaliplatin and fluoropyrimidine chemotherapy administered over 6 months
is the standard adjuvant regimen for patients with high-risk stage II or III colorectal cancer. …
is the standard adjuvant regimen for patients with high-risk stage II or III colorectal cancer. …
[HTML][HTML] SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for …
…, MP Saunders, J Cassidy, NH Hollander… - British journal of …, 2018 - nature.com
BACKGROUND The Short Course Oncology Therapy (SCOT) study is an international,
multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-…
multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-…
Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The …
LH Jensen, ML Kjaer, FO Larsen, NH Hollander… - 2023 - ascopubs.org
LBA3503 Background: Locally advanced colon cancer presents a therapeutic challenge
regarding improving survival and minimizing side effects by optimizing the timing of surgical …
regarding improving survival and minimizing side effects by optimizing the timing of surgical …
Potential prognostic factors of downstaging following preoperative chemoradiation for high rectal cancer
…, RP Vogelsang, S Janssen, SE Schild, NH Holländer… - In Vivo, 2018 - iv.iiarjournals.org
Background/Aim: Treatment for high rectal cancers, particularly the value of preoperative
treatment, is controversial. In our previous study, downstaging by preoperative chemoradiation …
treatment, is controversial. In our previous study, downstaging by preoperative chemoradiation …
Preliminary results from a prospective study comparing white blood cell and neutrophil counts from a laboratory to those measured with a new device in patients with …
…, CL Lindhardt, R Vonthein, D Rades, NH Holländer - in vivo, 2018 - iv.iiarjournals.org
Background/Aim: If blood tests were performed at home, unnecessary trips of patients for
chemotherapy could be avoided. The HemoCue® WBC DIFF device was tested at home by 14 …
chemotherapy could be avoided. The HemoCue® WBC DIFF device was tested at home by 14 …